Diabetes and cardiovascular disease: Focus on glucagon-like peptide-1 based therapies

Therapeutic Advances in Drug Safety

Volumn 3, Issue 4, 2012, Pages 185-201

  Stranges, Paul ^a   Khanderia, Ujjaini ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cardiovascular markers; exenatide; GLP 1 receptor agonists; incretin; liraglutide; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; FATTY ACID; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL PRACTICE; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIUM; GLYCEMIC CONTROL; HEART FUNCTION; HEART MUSCLE; HEART RATE; HUMAN; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 84868668557     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612454290     Document Type: Review

References (107)

1. Adler A. Shaw E. Stokes T. Ruiz F. and Guideline Development Group (2009) Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 338: b1668.
2. Amori R. Lau J. Pittas A. (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194–206.
3. Astrup A. Carraro R. Finer N. Harper A. Kunesova M. (2011) Safety, tolerability and sustained weight loss over 2 years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). doi: 10.1038/ijo.2011.15810.1038/ijo.2011.158.
4. Astrup A. Rossner S. Van Gaal L. Rissanen A. Niskanen L. Al Hakim M. (2009) Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 374: 1606–1616.
5. ATP III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497.
6. Baggio L. Huang Q. Brown T. Drucker D. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492–2500.
7. Ban K. Kim K. Cho C. Sauvé M. Diamandis E. (2010) Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520–1531.
8. Ban K. Noyan-Ashraf M. Hoefer J. Bolz S. Drucker D. Husain M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340–2350.
9. Barragan J. Rodriguez R. Blazquez E. (1994) Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266: E459–E466.
10. Basu A. Charkoudian N. Schrage W. Rizza R. Basu R. Joyner M. (2007) Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293: E1289–E1295.
11. Bell D. (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26: 2433–2441.
12. Bell D. O–Keefe J. Jellinger P. (2008) Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 14: 112–124.
13. Bergenstal R. Wysham C. Macconell L. Malloy J. Walsh B. Yan P. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376: 431–439.
14. Best J. Hoogwerf B. Herman W. Pelletier E. Smith D. Wenten M. (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34: 90–95.
15. Bjerre Knudsen L. Madsen L. Andersen S. Almholt K. de Boer A. Drucker D. (2010) Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151: 1473–1486.
16. Blonde L. Klein E. Han J. Zhang B. Mac S. (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436–447.
17. Bojanowska E. Stempniak B. (2000) Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept 91: 75–81.
18. Bose A. Mocanu M. Carr R. Brand C. Yellon D. (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146–151.
19. Brubaker P. Drucker D. (2004) Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653–2659.
20. Buse J. Bergenstal R. Glass L. Heilmann C. Lewis M. Kwan A. (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154: 103–112.
21. Buse J. Drucker D. Taylor K. Kim T. Walsh B. Hu H. (2010) DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33: 1255–1261.
22. Buse J. Henry R. Han J. Kim D. Fineman M., Baron, A. (2004a) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635.
23. Buse J. Rosenstock J. Sesti G. Schmidt W. Montanya E. Brett J. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.
24. Buse J. Tan M. Prince M. Erickson P. (2004b) The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6: 133–156.
25. Cleveland J. Meldrum D. Brian S. Cain B. Banerjee A. Alden H. (1997) Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 96: 29–32.
26. Courreges J. Vilsbøll T. Zdravkovic M. Le-Thi T. Krarup T. Schmitz O. (2008) Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 25: 1129–1131.
27. Deacon C. Nauck M. Toft-Nielsen M. Pridal L. Willms B. Holst J. (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126–1131.
28. DeFronzo R. Ratner R. Han J. Kim D. Fineman M. Baron A. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100.
29. Derosa G. Maffioli P. Salvadeo S. Ferrari I. Ragonesi P. Querci F. (2010) Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 12: 233–240.
30. Diamant M. Van Gaal L. Stranks S. Northrup J. Cao D. Taylor K. (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375: 2234–2243.
31. Diaz A. Bourassa M. Guertin M. Tardif J. (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26: 967–974.
32. Dore D. Bloomgren G. Wenten M. Hoffman C. Clifford C. Quinn S. (2011) A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13: 559–566.
33. Drucker D. Buse J. Taylor K. Kendall D. Trautmann M. Zhuang D. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240–1250.
34. Drucker D. Nauck M. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696–1705.
35. Duckworth W. Abraira C. Moritz T. Reda D. Emanuele N. Reavan P. for the VADT Investigators. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129–139.
36. Dunn E. Philippou H. Ariens R. Grant P. (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49: 1071–1080.
37. Elashoff M. Matveyenko A. Gier B. Elashoff R. Butler P. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150–156.
38. Fox C. Coady S. Sorlie P. D–Agostino R. Pencia M. Vasan R. (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115: 1544–1550.
39. Fox C. Pencina M. Wilson P. Paynter N. Vasan R. D–Agostino R. (2008) Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in The Framingham Heart Study. Diabetes Care 31: 1582–1584.
40. Garber A. Henry R. Ratner R. Garcia-Hernandez P. Rodriguez-Pattzi H. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473–481.
41. Garber A. Henry R. Ratner R. Hale P. Chang C. Bode B. (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13: 348–356.
42. Garg R. Chen W. Pendergrass M. (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33: 2349–2354.
43. Gautier J. Choukem S. Girard J. (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34(Suppl. 2): S65–S72.
44. Gerstein H. Miller M. Byington R. Goff D. Bigger J. Buse J. for the Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559.
45. Gill A. Hoogwerf B. Burger J. Bruce S. Macconell L. Yan P. (2010) Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9: 6.
46. Golpon H. Puechner A. Welte T. Wichert P. Feddersen C. (2001) Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102: 81–86.
47. Green B. Hand K. Dougan J. McDonnell B. Cassidy R. (2008) GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478: 136–142.
48. Haffner S. Lehto S. Ronnemaa T. Pyorala K. Laakso M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234.
49. Heine R. Van Gaal L. Johns D. Mihm M. Widel M. Brodows R. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143: 559–569.
50. Holst J. (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409–1439.
51. Howard B. Howard W. (1994) Dyslipidemia in non-insulin-dependent diabetes mellitus. Endocr Rev 15: 263–274.
52. Jendle J. Nauck M. Matthews D. Frid A. Hermansen K. During M. (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11: 1163–1172.
53. Juutilainen A. Lehto S. Ronnemaa T. Pyorala K. Laakso M. (2005) Type 2 diabetes as a ‘coronary heart disease equivalent–: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28: 2901–2907.
54. Kahn S. Haffner S. Heise M. Herman W. Holman R. Jones N. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443.
55. Karpe F. Steiner G. Uffelman K. Olivecrona T. Hamsten A. (1994) Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106: 83–97.
56. Kendall D. Bhole D. Guan X. Nielsen M. Trautmann M. Wintle M. (2006) Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1c, and body weight in patients treated with type 2 diabetes mellitus. Diabetologia 49: 475.
57. Kendall D. Riddle M. Rosenstock J. Zhuang D. Kim D. Fineman M. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091.
58. Klonoff D. Buse J. Nielsen L. Guan X. Bowlus C. Holcombe J. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275–286.
59. Koska J. Schwartz E. Mullin M. Schwenke D. Reaven P. (2010) Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 33: 1028–1030.
60. Liutkus J. Rosas Guzman J. Norwood P. Pop L. Northrup J. Cao D. (2010) A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 12: 1058–1065.
61. Mannucci E. Monami M. Lamanna C. Gori F. Marchionni N. (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19: 604–612.
62. Marre M. Shaw J. Brandle M. Bebakar W. Kamaruddin N. Strand J. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26: 268–278.
63. Meier J. Gethmann A. Gotze O. Gallwitz B. Holst J. Schmidt W. (2006) Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49: 452–458.
64. Miura T. (1990) Does reperfusion induce myocardial necrosis? Circulation 82: 1070–1072.
65. Monami M. Cremasco F. Lamanna C. Colombi C. Desideri C. Iacomelli I. (2011) Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 215764.
66. Moretto T. Milton D. Ridge T. Macconell L. Okerson T. Wolka A. (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30: 1448–1460.
67. Mudaliar S. Henry R. (2009) Incretin therapies: effects beyond glycemic control. Am J Med 122: S25–S36.
68. Nathan D. Buse J. Davidson M. Ferrannini E. Holman R. Sherwin R. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52: 17–30.
69. National Institute for Health and Clinical Experience (2010) NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Available at: http://guidance.nice.org.uk/CG66 (accessed 20 October 2011).
70. Nauck M. Frid A. Hermansen K. Shah N. Tankova T. Mitha I. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84–90.
71. Nauck M. Duran S. Kim D. Johns D. Northrup J. Festa A. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259–267.
72. Nauck M. Homberger E. Siegel E. Allen R. Eaton R. (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492–498.
73. Nauck M. Wollschlager D. Werner J. Holst J. Orskov C. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546–1553.
74. J., Neumiller, Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors, J Am Pharm Assoc, (Suppl. 1), (2009), 49, S16, S29
75. Nikolaidis L. Elahi D. Shen Y. Shannon R. (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401–H2408.
76. Nikolaidis L. Mankad S. Sokos G. Miske G. Shah A. Elahi D. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965.
77. Noyan-Ashraf M. Momen M. Ban K. Sadi A. Zhou Y. Riazi A. (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975–983.
78. Nystrom T. Gonon A. Sjoholm A. Pernow J. (2005) Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125: 173–177.
79. Okerson T. Yan P. Stonehouse A. Brodows R. (2010) Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23: 334–339.
80. Ozyazgan S. Kutluata N. Afsar S. Ozdas S. Akkan A. (2005) Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74: 119–126.
81. Pannacciulli N. Le D. Salbe A. Chen K. Reiman E. Tatatanni P. (2007) Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 35: 511–517.
82. Parks M. Rosebraugh C. (2010) Weighing risks and benefits of liraglutide – the FDA–s review of a new antidiabetic therapy. N Engl J Med 362: 774–777.
83. Patel A. MacMahon S. Chalmers J. Neal B. Billot L. Woodward M. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572.
84. Patsch J. Miesenbock G. Hopferwieser T. Muhlberger V. Knapp E. Dunn J. (1992) Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12: 1336–1345.
85. Plutzky J. Garber A. Toft A. and Poulter N. (2009) Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in T2D. Diabetologia 52: A762-P.
86. Raschi E. Piccinni C. Poluzzi E. Marchesini G. De Ponti F. (2011) The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 19 October (epub ahead of print).
87. Ray K. Seshasai S. Wijesuriya S. Sivakumaran R. Nethercott S. Preiss D. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765–1772.
88. Rodbard H. Jellinger P. Davidson J. Einhorn D. Garber A. Grunberger G. (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15: 540–559.
89. Ross S. Ekoe J. (2010) Incretin agents in type 2 diabetes. Can Fam Physician 56: 639–648.
90. Russell-Jones D. Vaag A. Schmitz O. Sethi B. Lalic N. Antic S. (2009) Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046–2055.
91. Sarwar N. Gao P. Seshasai S. Gobin R. Kaptoge S. Di Angelantonio E. (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215–2222.
92. Selvin E. Coresh J. Golden S. Brancati F. Folsom A. Steffs M. (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165: 1910–1916.
93. Sokos G. Bolukoglu H. German J. Hentosz T. Magovern G. Maher T. (2007) Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100: 824–829.
94. Sokos G. Nikolaidis L. Mankad K. Elahi D. Shannon R. (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694–699.
95. Tabet F. Rye K. (2009) High-density lipoproteins, inflammation and oxidative stress. Clin Sci 116: 87–98.
96. Tatarkiewicz K. Smith P. Sablan E. Polizzi C. Aumann D. Villascaz C. (2010) Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 299: E1076–E1086.
97. Thomson Reuters (2012) Red Book Online. Available at http://www.micromedex.com/products/redbook/awp/ (accessed 25 June 2012).
98. Timmers L. Henriques J. De Klejn D. Devries J. Kemperman H. Steendijk P. (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501–510.
99. Tushuizen M. Diamant M. Heine R. (2005) Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 81: 1–6.
100. Vilsbøll T. Brock B. Perrild H. Levin K. Lervang H. Kolendorf K. (2008) Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25: 152–156.
101. Vilsbøll T. Christensen M. Junker A. Knop F. Gluud L. (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771.
102. Vilsbøll T. Krarup T. Deacon C. Madsbad S. Holst J. (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609–613.
103. Viswanathan P. Chaudhuri A. Bhatia R. Al-Atrash F. Mohanty P. Dandona P. (2007) Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 13: 444–450.
104. Yu M. Moreno C. Hoagland K. Dahly A. Ditter K. Mistry M. (2003) Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125–1135.
105. Zinman B. Gerich J. Buse J. Lewin A. Schwartz S. Raskin P. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224–1230.
106. Zinman B. Hoogwerf B. Duran Garcia S. Milton D. Giaconia J. Kim D. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146: 477–485.
107. Zhao T. Parikh P. Bhashyam S. Bolukoglu H. Poornima I. Shen T. (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106–1113.